These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 31478786)

  • 81. Molecular epidemiology of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae in Seville.
    Iraurgui P; Torres MJ; Aznar J
    Enferm Infecc Microbiol Clin; 2012 Apr; 30(4):180-3. PubMed ID: 22365183
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Fluoroquinolone resistance in Mycoplasma gallisepticum: DNA gyrase as primary target of enrofloxacin and impact of mutations in topoisomerases on resistance level.
    Reinhardt AK; Kempf I; Kobisch M; Gautier-Bouchardon AV
    J Antimicrob Chemother; 2002 Oct; 50(4):589-92. PubMed ID: 12356806
    [TBL] [Abstract][Full Text] [Related]  

  • 83. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
    Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
    J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Frequency of DNA gyrase and topoisomerase IV mutations and plasmid-mediated quinolone resistance genes among Escherichia coli and Klebsiella pneumoniae isolated from urinary tract infections in Azerbaijan, Iran.
    Azargun R; Soroush Barhaghi MH; Samadi Kafil H; Ahangar Oskouee M; Sadeghi V; Memar MY; Ghotaslou R
    J Glob Antimicrob Resist; 2019 Jun; 17():39-43. PubMed ID: 30445211
    [TBL] [Abstract][Full Text] [Related]  

  • 85.
    Mohamed NM; Zakaria AS; Edward EA; Abdel-Bary A
    Pol J Microbiol; 2019; 68(1):59-69. PubMed ID: 31050254
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases.
    Black MT; Stachyra T; Platel D; Girard AM; Claudon M; Bruneau JM; Miossec C
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3339-49. PubMed ID: 18625781
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
    Lin L; Chang LW; Tsai CY; Hsu CH; Chung DT; Aronstein WS; Ajayi F; Kuzmak B; Lyon RA
    Antimicrob Agents Chemother; 2010 Jan; 54(1):405-10. PubMed ID: 19884368
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Multicenter study in Taiwan of the in vitro activities of nemonoxacin, tigecycline, doripenem, and other antimicrobial agents against clinical isolates of various Nocardia species.
    Lai CC; Liu WL; Ko WC; Chen YH; Tan HR; Huang YT; Hsueh PR
    Antimicrob Agents Chemother; 2011 May; 55(5):2084-91. PubMed ID: 21343461
    [TBL] [Abstract][Full Text] [Related]  

  • 89. In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria.
    Huband MD; Bradford PA; Otterson LG; Basarab GS; Kutschke AC; Giacobbe RA; Patey SA; Alm RA; Johnstone MR; Potter ME; Miller PF; Mueller JP
    Antimicrob Agents Chemother; 2015 Jan; 59(1):467-74. PubMed ID: 25385112
    [TBL] [Abstract][Full Text] [Related]  

  • 90. In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.
    Yamamoto K; Yanagihara K; Sugahara K; Imamura Y; Seki M; Izumikawa K; Kakeya H; Yamamoto Y; Hirakata Y; Kamihira S; Kohno S
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3572-5. PubMed ID: 19451290
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Tentative clinical breakpoints and epidemiological cut-off values of nemonoxacin for Streptococcus pneumoniae and Staphylococcus aureus isolates associated with community-acquired pneumonia.
    Jean SS; Chang LW; Hsueh PR
    J Glob Antimicrob Resist; 2020 Dec; 23():388-393. PubMed ID: 33207229
    [TBL] [Abstract][Full Text] [Related]  

  • 92. [In vitro evaluation of the antibacterial activity of nemonoxacin against
    Jiang GL; Wang F; Xue Y; Jia JN; Huang HR
    Zhonghua Jie He He Hu Xi Za Zhi; 2020 Dec; 43(12):1061-1065. PubMed ID: 33333640
    [No Abstract]   [Full Text] [Related]  

  • 93. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae.
    Chotikanatis K; Kohlhoff SA; Hammerschlag MR
    Antimicrob Agents Chemother; 2014; 58(3):1800-1. PubMed ID: 24366753
    [TBL] [Abstract][Full Text] [Related]  

  • 94. [
    Li B; Guo Q; Chu HQ
    Zhonghua Jie He He Hu Xi Za Zhi; 2021 Nov; 44(11):947-952. PubMed ID: 34758520
    [No Abstract]   [Full Text] [Related]  

  • 95. In vitro activity of Ozenoxacin against quinolone-susceptible and quinolone-resistant gram-positive bacteria.
    López Y; Tato M; Espinal P; Garcia-Alonso F; Gargallo-Viola D; Cantón R; Vila J
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6389-92. PubMed ID: 24080666
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Review of nemonoxacin with special focus on clinical development.
    Qin X; Huang H
    Drug Des Devel Ther; 2014; 8():765-74. PubMed ID: 25045247
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis.
    Zhao M; Chi Z; Pan X; Yin Y; Tang W
    Int J Environ Res Public Health; 2022 Apr; 19(8):. PubMed ID: 35457683
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Interaction of Quinolones Carrying New R1 Group with
    Park JH; Yamaguchi T; Ouchi Y; Koide K; Pachanon R; Chizimu JY; Mori S; Kim H; Mukai T; Nakajima C; Suzuki Y
    Microb Drug Resist; 2021 Dec; 27(12):1616-1623. PubMed ID: 34077282
    [No Abstract]   [Full Text] [Related]  

  • 99. In vitro antibacterial activity of OPS-2071 against Gram-positive and Gram-negative enteropathogenic bacteria.
    Oka D; Changkwanyeun R; Yamaguchi T; Nakajima C; Suzuki Y; Matsumoto M
    J Antimicrob Chemother; 2022 Nov; 77(12):3248-3255. PubMed ID: 36101508
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Nonoptimal DNA topoisomerases allow maintenance of supercoiling levels and improve fitness of Streptococcus pneumoniae.
    Balsalobre L; Ferrándiz MJ; de Alba G; de la Campa AG
    Antimicrob Agents Chemother; 2011 Mar; 55(3):1097-105. PubMed ID: 21173181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.